Friday December 05 2008 | Biotechnology feed | All feeds
September Archive 2004 - have your press release here?
Improving levodopa-based complications to advance Parkinson's Disease therapies
Solexa and Lynx merge to create future sequencing powerhouse
Solexa Announces Successful Closure of $14.4m financing
Sirenade Pharmaceuticals appoints Lynn Butler as CEO and restructures management team
The Last Bastion: U.S. Pharmaceutical Prices Under Pressure
GENOME express offers 10,000 free sequences to mark 10 years in DNA sequence analysis business
Increased HIV survival rates generate upcoming treatment challenges
The Eighth European Biotechnology Crossroads lines up wide range of events to give buzz to bio-business
Pharma License Exchange™ North America's most efficient partnering forum Oct. 27-28, 2004
Sankyo's angiotensin II receptor blocker (ARB) olmesartan medoxomil demonstrates antiinflammatory activity in hypertensive patients.
SWITCH Biotech AG: Founding of a rescue company after insolvency
Inpharmatica Announces Biopendium Online(TM) Subscription with Chugai
Inpharmatica Announces Biopendium Online(TM) Subscription with Chugai UPDATED
Novagali Pharma completes second financing round of 14.2 million euros UPDATED
Kereos and Dow Sign Licensing Agreement for Novel Targeted Imaging Agents
Management's impact on biotechnology firm valuation and stock price
Novagali Pharma completes second financing round of 14.2 million euros
Omnitrope deferral casts doubt over biogeneric development
Harsh environment threatens antibacterial development
LUDWIG INSTITUTE FOR CANCER RESEARCH AND POWDERMED INITIATE A PHASE I CLINICALTRIAL FOR A NOVEL THERAPEUTIC CANCER VACCINE
OXFORD BIOMEDICA SIGNS LICENSE AGREEMENT WITH MASSACHUSETTS GENERAL HOSPITAL, BOSTON UNIVERSITY AND DANA-FARBER CANCER INSTITUTE
Pill Proof - Medication Compliance Kit ... A Life Saver
Agilent Technologies' Venture Unit Invests in Genospectra Inc.'s Series C Round of Funding
Capsulution NanoScience AG Fast and Economical Production of Surface-modified Nano- and Microstructures
GlaxoSmithKline's IkappaB kinase 2 (IKK-2) inhibitor, TCPA-1 as a potential next generation disease modifying antirheumatic drug (DMARD) for the treatment of rheumatoid arthritis
Bayer Technology Services and Physiomics sign collaboration
Valuing In-Licensed Therapeutics and Technologies - Biotech and Pharmaceutical Congress
Grant Instruments - Do the shimmy shake with Grant / Boekel
atugen and Aventis to collaborate in identifying siRNA compounds with the potential for therapeutic development
Xantos Secures Additional Finance of €4 Million ($4.8 Million)
Peakdale launches mid-year intermediates catalogue
NEW DRUG CANDIDATE FOR SEVERE ASTHMA FROM CAMBRIDGE ANTIBODY TECHNOLOGY (CAT) STARTS CLINICAL TRIALS
Trials & Tribulations: Advances in the Development of Histone Deacetylase (HDAC) Inhibitors for the Treatment of Cancer
Patient compliance is a $30 billion complaint
Success of 'Genomes to Systems' Conference highlights the Move to Systems Biology
Agilent Technologies Awarded 2004 Lilly Global Supplier Award
thinkPharm.com announces drugs facing patent expirations in September 2004
IntegraGen appoints a Vice President Business Development
Archemix to Present at Thomas Weisel Partners' Healthcare Tailwinds 2004 Conference
CAMBRIDGE ANTIBODY TECHNOLOGY (CAT) ANNOUNCES FINANCIAL RESULTS FOR THE NINE MONTHS ENDED 30 JUNE 2004
BIOPHARMA: New Third Edition of Biopharmaceutical Reference Published
New study reveals that reversing albuminuria reduces cardiovascular events in patients with diabetic nephropathy
BioPortfolio Bulletin - Auction of Biotechnology Facility with Research and Development, Vivarium and Plant Support Equipment
DailyUpdates - Today's breaking journal articles & press releases selected for the drug development sector
Isotechnika's search for a partner continues
New research encourages changes in the treatment and prevention of deep vein thrombosis in cancer patients
CXR Biosciences Ltd Launches Investigative Toxicology Service Using Agilent Microarray Technology for Transcriptional Profiling
Agilent Technologies Introduces Industry-First Features in Pharmaceutical Method Validation Software
CTM Biotech - Appointment of Malcolm Brattle as Non-Executive Director
OXFORD BIOMEDICA ANNOUNCES POSITIVE INTERIM PHASE II RESULTS WITH TROVAX IN COLORECTAL CANCER
Dompe researchers develop chemokine receptor CXCR1 antagonist for the prevention of acute transplant rejection, chronic ischemic conditions and inflammatory disorders
Agilent Technologies Introduces Whole Mouse Genome Microarray
Solexa Announces the Appointment of John West as New CEO
Toxicity problems continue to slow the development of CDK inhibitors
Targeted therapies the aim for breast cancer treatment
BioNewsCast Press Release Service 2003 Archive
BioNewsCast Press Release Service 2002 Archive
Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.
All rights reserved. All other trademarks recognized. Copyright © 1997-2008 - BioPortfolio Limited.
